Drug intelligence / Profile preview

NB2221

Development stage: Preclinical
Lead developer: University of Mississippi
Modality: Small Molecules
Administration: Oral

Overview

**NB2221** is an investigational cannabinoid-based therapeutic candidate developed by Nemus Bioscience using University of Mississippi intellectual property covering transmucosal cannabinoid delivery technology designated UM 1490. It was intended for symptomatic treatment of spasticity associated with multiple sclerosis. Publicly available information does not identify the precise cannabinoid active ingredient, its composition, receptor selectivity, dosage form, or clinical development phase.

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on NB2221.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NB2221.

Explore the full profile